Company Overview: OncoCyte

Industry News

7 Dec

OncoCyte Presents Positive Data from its Liquid Biopsy Breast Cancer Diagnostic Test at the San Antonio Breast Cancer Symposium

ALAMEDA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today presented positive data from its most recent breast cancer diagnostic test study at the 2017 San Antonio Breast Cancer Symposium (SABCS). The data were presented by Philip...

Read more

27 Nov

OncoCyte Corporation to Participate in the Benchmark Company, LLC Micro Cap Discovery One-on-One Conference

ALAMEDA, Calif., Nov. 27, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett, President and Chief Executive Officer, and Mitch Levine, Chief Financial Officer, will participate in the Benchmark Company, LLC Micro Cap...

Read more

15 Nov

OncoCyte Reports Third Quarter 2017 Financial Results

ALAMEDA, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported financial results for the quarter ended September 30, 2017, and provided an update on the Clinical Validation Study of DetermaVu™, the Company’s liquid biopsy lung...

Read more

6 Nov

OncoCyte to Report Third Quarter 2017 Financial Results on November 14, 2017

ALAMEDA, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended September 30, 2017, on Tuesday, November 14, 2017, after the...

Read more

27 Sep

OncoCyte Announces Successful Completion of CLIA Lab Validation Study of its DetermaVu™ Lung Cancer Diagnostic Test; Clinical Validation Study Initiated

ALAMEDA, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive, blood-based liquid biopsy tests to assist in the early detection of cancer, announced today that its CLIA laboratory has successfully completed a rigorous validation study of DetermaVu™, OncoCyte’s diagnostic test for lung cancer. In...

Read more

18 Sep

OncoCyte Reports Positive Analytical Validation Study Results of DetermaVu™ Lung Cancer Diagnostic Test

ALAMEDA, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive blood-based liquid biopsy tests to assist in the early detection of cancer, announced today positive final results from the Analytical Validation Study of its liquid biopsy lung cancer diagnostic test, DetermaVU™. The data were...

Read more

7 Sep

OncoCyte Receives CLIA Certification for its Cancer Diagnostics Laboratory

ALAMEDA, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) — OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that its clinical laboratory facility located in Alameda, California, has received Clinical Laboratory Improvements Amendments (CLIA) certification of registration from the Centers for Medicare...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address